

ACSAP 2021 Book 3 (*Oncology and Nephrology Care*)

Release date: November 15, 2021

BCACP test deadline: 11:59 p.m. (Central) on May 16, 2022.

ACPE test deadline: 11:59 p.m. (Central) on November 15, 2024.



Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy

and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

ACSAP Target Audience: The target audience for ACSAP 2021 Book 2 (*Oncology and Nephrology Care*) is board-certified and advanced level ambulatory care clinical pharmacists who provide care for patients with cancer and nephrologic complications.

Module 1 (4.5 CPE) Oncology and Nephrology Care I

UAN: 0217-9999-21-254-H01-P

Chapter: Treatment and Supportive Care for Multiple Myeloma

Learning Objectives

1. Assess the epidemiology, pathophysiology, molecular biology, and disease course for patients with a diagnosis of multiple myeloma (MM).
2. Develop an induction treatment strategy for initial treatment of MM on the basis of a patient's candidacy for a stem cell transplant, cytogenetics, comorbidities, and patient preference.
3. Evaluate initial response to induction treatment for newly diagnosed MM, and convert a patient to an appropriate maintenance regimen, as applicable.
4. Design a plan of care and salvage regimen for relapsed, refractory MM for a patient on the basis of treatment history, medical comorbidities, and toxicity profile.
5. Evaluate patients for potential toxicities from MM treatment regimens, and recommend appropriate therapy-specific supportive care.

Chapter: Breast Cancer

Learning Objectives

1. Evaluate the role risk factors play in the development of breast cancer.
2. Analyze the current screening guidelines to determine appropriate tools and testing intervals.
3. Develop a treatment plan for the prevention of breast cancer in a patient with a high risk of developing invasive disease.
4. Design a treatment plan for a patient with newly diagnosed, early stage breast cancer taking into consideration prognostic factors and staging.

5. Assess the impact of hormonal status, HER2 status, and other genomic markers in a treatment regimen for a patient with newly diagnosed, early stage breast cancer and in the metastatic setting.

Module 2 (4.5 CPE) Oncology and Nephrology Care II

UAN: 0217-9999-21-255-H01-P

Chapter: Anticancer Therapy–Induced Nausea and Vomiting.

Learning Objectives

1. Evaluate for patient- and treatment-related risk factors for chemotherapy-induced nausea and vomiting (CINV).
2. Distinguish between drug therapy used for the prevention and management of CINV.
3. Develop a patient and anticancer treatment appropriate antiemetic regimen for the prevention and management of CINV.
4. Develop a patient- and anticancer treatment–specific antiemetic regimen for the prevention and management of CINV in older adults and in pediatric patients with cancer.

Chapter: Anemia Management in the Biosimilar Era

Learning Objectives

1. Develop electronic health record tools to help identify and mitigate contributing factors to anemia.
2. Design treatment plans for correcting nutritional deficiency anemias that consider patient tolerability, effectiveness, and cost.
3. Distinguish the differences between biologic and biosimilar erythropoiesis-stimulating agents (ESAs) in selecting an ESA for use.
4. Evaluate the risk-benefit of treating anemia in patients with cancer, with chronic kidney disease, or after gastric bypass surgery.

Module 3 (5.0 CPE) Oncology and Nephrology Care III

UAN: 0217-9999-21-256-H01-P

Chapter: Nephrotic Syndrome

Learning Objectives

1. Assess patients for the etiology and pathophysiology of nephrotic syndrome.
2. Evaluate patients with glomerular disease for nephrotic syndrome.
3. Develop therapeutic options to manage common complications of nephrotic syndrome
4. Design appropriate immunosuppressive therapy for specific glomerular disease with nephrotic syndrome

Chapter: Drug-Induced Kidney Injury

Learning Objectives

1. Evaluate a patient’s risk factors for drug-induced kidney injury.

2. Assess a patient for the presence of drug-induced kidney injury using diagnostic and physiologic findings.
3. Evaluate drug and drug dosing regimens in patients with risk factors for drug-induced kidney injury.
4. Design a plan to prevent or manage drug-induced kidney injury.

Module 4 (4.0 CPE) Oncology and Nephrology Care IV

UAN: 0217-9999-21-257-H01-P

Interactive Case: Monitoring Patients on Oral Chemotherapy

Learning Objectives

1. Evaluate the pharmacy practice standards for the management of oral oncolytic therapy as outlined by recent guidelines
2. Analyze the appropriateness of oral oncolytic usage, including line of treatment, dosing, frequency, drug-disease interactions, drug-drug interactions, and drug-food interactions
3. Design appropriate patient education for patients initiating a new oral oncolytic treatment
4. Develop a thorough adherence and monitoring plan for a patient initiating a new oral oncolytic treatment.

Interactive Case: Cancer Immune Checkpoint Inhibitors and Long-term Toxicity

Learning Objectives

1. Distinguish differences between immunotherapy agents.
2. Assess patients for long-term toxicities of immune checkpoint inhibitors and design appropriate management strategies.
3. Develop monitoring plans for patients on immune checkpoint inhibitors and concurrent corticosteroids.
4. Assess risk of immune-related adverse events in special populations.

Interactive Case: Drug Dosing in Kidney Disease

Learning Objectives (A)

1. Assess kidney function in a patient with chronic kidney disease.
2. Evaluate pharmacokinetic and pharmacodynamics alterations expected in patients with chronic kidney disease.
3. Develop appropriate dosing and monitoring plans for patients with chronic kidney disease.
4. Evaluate literature supporting pharmacist role in improving medication outcomes in area of drug dosing for patients with chronic kidney disease.